Mark Brantly, MD
Professor of Medicine
Vice Chair of Research, Department of Medicine
Alpha-1 Foundation Research Professor
mark.brantly@medicine.ufl.edu

---

Personal Statement

I am a senior investigator specializing in rare lung disease translational research with a focus on alpha-1-antitrypsin deficiency, gene therapy, pulmonary fibrosis and alveolar macrophage function.

I have mentored a number of faculty in bench to bedside research at the NIH Clinical Center and the University of Florida. I am a former K24 grantee, a mentor on 2 T32 programs and the UF MD/PhD program. My role on applicant’s grant is to provide molecular biology support, access to lung tissue and guidance on the transition to patient-oriented research.

---

Lab Faculty and Staff

Professor of Medicine

Mark Brantly

Vice Chair of Research, Department of Medicine Alpha-1 Foundation Research Professor

ASSISTANT DIRECTOR, ALPHA-1 ATD PROGRAM

Tammy Flagg

Biological Scientist

Alek Aranyos

Laboratory Technician

Calvin Gould

Research Assistant Professor

Nazli Khodayari

Research Scientist

Jungnam Lee

Research Scientist

Yuanqing Lu

Graduate Assistant

Naweed Mohammad

Laboratory Manager

Regina Oshins

research administrator

Emily Mak

ADMINISTRATIVE SPECIALIST I

Lisa Oppel

LABORATORY TECHNICIAN I

Jenna Russom

Laboratory Technician I

Chancellor McGriff

Laboratory Technician I

William Bowers

REsearch Support

Ongoing

• Inhibrx 101 LP, ” An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD),” Brantly (PI) 1/1/2018-12/31/2019
• Adverum Biotechnologies, Inc., “Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals with Alpha-1 Antitrypsin Deficiency,”  Brantly (PI) 1/1/2018-12/31/2019
• Kamada, LTD. “Follow up, surveillance study on patients who were exposed to inhaled AAT during the Kamada-AAT (inhaled)-006 study,” 1/1/2018-12/31/2018
• Alpha-1 Foundation Research Professorship/Fernandez Liver Research Grant Research Endowment/4PBA Mediated Alpha-1 Antitrypsin Secretion Rescue Brantly (PI) 12/8/1998-
• Alpha-1 Foundation / HHS-State of Florida/ Talecris Biotherapeutics/ HICL Principal Investigator Alpha-1 Foundation Tissue Bank/ ACT program/National AAT Screening Program/HICL AAT Screening Program, Brantly (PI) 7/1/2000
• Grifols National AAT Screening Program,  Brantly (PI) 7/1/2000-12/31/18
• NIH NCRR/Cincinnati Children’s Hospital Medical Center/LAM Foundation, “Quantitative Chest Computed Tomography Unmasking Emphysema Progression in Alpha-1 Antitrypsin Deficiency” Brantly (PI) 11/1/07-6/30/17

Completed

• NIH NCRR/Cincinnati Children’s Hospital Medical Center/LAM Foundation “The Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES),” Brantly (Site PI) 11/01/07- 06/30/2010
• Kamada, LTD.,”Phase II/III Randomized Double-Blind Comparison of Alpha-1 Proteinase Inhibitor(Kamada-API) with Prolastin,”Brantly (PI) 04/23/07- 01/17/10
• NIH/NIHLBI, “The Anti-Inflammatory Role of Alpha-1 Antitrypsin in the Lung (K24-HL004456)” Brantly (PI) 3/30/01-07/21/07
• Florida Department of Health, “Tobacco Smoke-Induced Cell Injury in Lung Compartments,” Brantly (CO-I) 08/01/04-03/31/08
• Washington University, “Washington University Testing Services Agreement,”Brantly (PI), 02/12/08 -06/30/10